BioNTech and Pfizer present bispecific cancer data at ASCO, FDA chief notes optimism

At the American Society of Clinical Oncology meeting, BioNTech and Pfizer highlighted early results from bispecific antibody programs aimed at lung cancer. The companies described the data as promising, suggesting the approach could expand the immunotherapy toolbox.

The presentation emphasized the potential of bispecifics to engage multiple targets simultaneously, a strategy that may improve response rates compared with existing therapies.

FDA Oncology Center of Excellence director Rick Pazdur commented on the data, offering a silver‑lining perspective and expressing optimism about the regulatory pathway for such innovative treatments.

Analysts view the upbeat reception as a positive signal for the companies’ pipelines and for investors tracking next‑generation immuno‑oncology assets.